Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P.

Eur Urol. 2019 Dec;76(6):732-739. doi: 10.1016/j.eururo.2019.07.009. Epub 2019 Jul 20.

PMID:
31331782
2.

Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.

De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, De Man K, Delrue L, Lambert B, Ost P.

Eur Urol. 2019 May;75(5):826-833. doi: 10.1016/j.eururo.2018.10.044. Epub 2018 Nov 29.

PMID:
30503072
3.

Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.

Tran S, Jorcano S, Falco T, Lamanna G, Miralbell R, Zilli T.

Am J Clin Oncol. 2018 Oct;41(10):960-962. doi: 10.1097/COC.0000000000000419.

PMID:
29315174
4.

Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.

Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, Ingrosso G.

Eur Urol Focus. 2017 Dec;3(6):538-544. doi: 10.1016/j.euf.2017.07.006. Epub 2017 Aug 8.

PMID:
28801240
5.

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, Guminski A, Eade T.

Eur Urol Oncol. 2018 Dec;1(6):531-537. doi: 10.1016/j.euo.2018.04.017. Epub 2018 May 23.

PMID:
31158100
6.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2019 Nov;5(6):1007-1013. doi: 10.1016/j.euf.2018.02.015. Epub 2018 Mar 10.

PMID:
29530632
7.

Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice.

Panje C, Zilli T, Pra AD, Arnold W, Brouwer K, Garcia Schüler HI, Gomez S, Herrera F, Khanfir K, Papachristofilou A, Pesce G, Reuter C, Vees H, Zwahlen D, Putora PM.

Radiat Oncol. 2019 Oct 16;14(1):177. doi: 10.1186/s13014-019-1383-0.

8.

Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.

Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R, Casamassima F, Surgo A, Miralbell R, De Meerleer G.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20. doi: 10.1016/j.clon.2016.04.040. Epub 2016 Apr 28.

PMID:
27133946
9.

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.

Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Christiansen H, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M.

Eur Urol Focus. 2019 Sep 5. pii: S2405-4569(19)30270-6. doi: 10.1016/j.euf.2019.08.012. [Epub ahead of print]

PMID:
31495759
10.

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.

Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR.

BMC Urol. 2019 Sep 9;19(1):84. doi: 10.1186/s12894-019-0515-z.

11.

Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.

Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D'agostino G, Corradini S, Alongi F, Scorsetti M.

Strahlenther Onkol. 2019 Sep 26. doi: 10.1007/s00066-019-01523-9. [Epub ahead of print]

PMID:
31559480
12.

Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.

Fodor A, Lancia A, Ceci F, Picchio M, Hoyer M, Jereczek-Fossa BA, Ost P, Castellucci P, Incerti E, Di Muzio N, Ingrosso G.

World J Urol. 2019 Dec;37(12):2607-2613. doi: 10.1007/s00345-018-2322-7. Epub 2018 May 11.

PMID:
29752513
13.

Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.

Lépinoy A, Silva YE, Martin E, Bertaut A, Quivrin M, Aubignac L, Cochet A, Créhange G.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):40-48. doi: 10.1007/s00259-018-4159-0. Epub 2018 Sep 28.

PMID:
30267117
14.

Re: Metastasis-Directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

Taneja SS.

J Urol. 2019 Dec 12:101097JU000000000000067701. doi: 10.1097/JU.0000000000000677.01. [Epub ahead of print] No abstract available.

PMID:
31829824
15.

Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".

Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien R, Lohaus F, Klass ND, Eble MJ, Imhoff D, Kahl H, Petersen C, Gerum S, Henkenberens C, Adebahr S, Hass P, Schrade E, Wendt TG, Hildebrandt G, Andratschke N, Sterzing F, Guckenberger M.

Lung Cancer. 2016 Jul;97:51-8. doi: 10.1016/j.lungcan.2016.04.012. Epub 2016 Apr 26.

PMID:
27237028
16.

Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.

Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, Santoni R.

Clin Genitourin Cancer. 2015 Aug;13(4):e279-e284. doi: 10.1016/j.clgc.2014.12.014. Epub 2014 Dec 30.

PMID:
25604915
17.

Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.

Verma V, Schonewolf CA, Cushman TR, Post CM, Doms A, Berman AT, DeVries M, Katz SI, Simone CB 2nd.

Clin Lung Cancer. 2018 Nov;19(6):502-510. doi: 10.1016/j.cllc.2018.07.005. Epub 2018 Jul 25.

PMID:
30111509
18.

Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.

Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, Muto M, Surgo A, Zerini D, Marvaso G, Timon G, Romanelli P, Rondi E, Comi S, Cattani F, Golino F, Mazza S, Matei DV, Ferro M, Musi G, Nolè F, de Cobelli O, Ost P, Orecchia R.

Clin Genitourin Cancer. 2017 Aug;15(4):e623-e632. doi: 10.1016/j.clgc.2017.01.004. Epub 2017 Jan 11.

PMID:
28185875
19.

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.

Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D'Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM.

Br J Cancer. 2017 Jun 6;116(12):1520-1525. doi: 10.1038/bjc.2017.103. Epub 2017 Apr 27.

20.

Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.

Horne ZD, Richman AH, Dohopolski MJ, Clump DA, Burton SA, Heron DE.

Lung Cancer. 2018 Jan;115:1-4. doi: 10.1016/j.lungcan.2017.10.014. Epub 2017 Nov 10.

PMID:
29290248

Supplemental Content

Support Center